The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
To achieve capital growth through investing in high growth, development stage biotechnology companies.
Find out MoreLondon South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The index seems to be holding some momentum now and the MA is on the up.
if anybody ever wondered on how are sales revenue numbers doing after the biotech selloff a few weeks ago, it is great! these are the top 2 holdings in IBT's portfolio :- http://blogs.barrons.com/stockstowatchtoday/2014/05/09/gilead-sciences-sovaldi-still-selling-biogens-tecfidera-launch-going-well/ IBT's portfolio :- http://www.investegate.co.uk/intnl--biotechnology--ibt-/rns/portfolio-update/201404141450417900E/
there seems to be renewed interest today...? anyway, IBT has been holding well at this level so I decided to top up again this morning. results from the sale of sovaldi also beat analyst estimations by almost 3 times(yes, that's 300%). and they have just started selling it in the european markets too. some hype Gilead Sciences as an "Apple in the making" hahaha. anyway, my confidence for IBT in the long run has returned.
Tomorrow shaping up to be a good day, shame your order didn't go through today ;-)
cheers mate. well we're not theonly ones feeling the pain...oddly enough, the share price started tanking after a bunch of director buys! http://www.investegate.co.uk/intnl--biotechnology--ibt-/rns/director-pdmr-shareholding/201402281540472616B/ my buy order towards closing didn't get triggered...but i plan to buy another batch after seeing today's closing price. perhaps tomorrow or friday.
syntaxity I defo mean well and I know how you feel! I'm not trying to persuade you to do anything and you need to do what you think is right. For me think no point getting out at the bottom then see it storm up, I'm more in BIOG than IBT but they are both in same boat. Biotechs will hit the bottom then be a buyers market, hopefully today but who knows! Futures are up in an hour or so we will know, Nasdaq did well yesterday but Biotechs were still down. All the best which ever way you go.
on the 20th of march the share price was 320p. today, at 248p, it has tanked > 20% in 3 weeks. if IBT isn't going to help me grow my cash, i'd rather cut my losses and place it into other shares that are trending up. also makes me wonder, why has management not released a statement? just look at the chart! i'm still holding but if there is another annihilation today, i'm out. even though this is now 30% undervalued as it stands and even though it will be a loss for me. but if IBT stabilises, i may top up! haha thanks for your advice, know/hope u mean well.
Personally I hold as the key biotech shares in IBT & BIOG went up yesterday even though the IBT price dropped. They've probably gone through the worst and will be snapped up soon. No point in selling at the bottom, biotech shares can go up quick when the move look at the swings over the last couple of years up and down. Up to you!!
well yeah but where is the bottom? there is a 35% upside now, valuation as recent as yesterday, as per below. at IBT's current share price, it has wiped out all my profit from another share. the half year results are coming soon. wondering whether to hold on for that or just bail out. to the market maker, if you are reading this, you sure have one sick way of giving people sleepless nights.
You can buy at about 245 now!
as of yesterday, the NAV of IBT is still 331p per share. http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11916716 if you buy a few at 260p today, that's a whopping 27% discount.
what's going on here? from 380p to 260p in less than 40 days. even the top 4 holdings in IBT's portfolio hasn't dropped that much. Biogen 7.2% Gilead 6.9% Regeneron 5.9% Celgene 5.6% IBT has dropped 30% from peak at the end of february while the rest has only devalued by 20% or less.
http://www.rttnews.com/2263386/gilead-profit-tops-estimates.aspx
http://seekingalpha.com/news/1654523-sovaldi-uptake-strong-despite-pricing-controversy
http://seekingalpha.com/article/2120063-gilead-sciences-strong-long-term-growth-at-a-bargain http://blogs.barrons.com/stockstowatchtoday/2014/04/02/gilead-sciences-what-if-sovaldi-sales-peak-quickly-fall-fast/?mod=BOLBlog and finally... "Gilead Sciences Inc. (NASDAQ: GILD) was the main reason that the biotech sector suffered its sell-off, based on the price inquiry for Sovaldi. Even after still being down by 13% from its peak, Gilead is worth almost $114 billion in market cap now. Price inquiries are not new — just ask Amgen. Gilead has said the new therapy can avoid the long-term medical expenses related to liver failure, cancer and transplants. The RBC team calls Gilead their most compelling buy, trading at only 10 times 2016 earnings. RBC even thinks that earnings will be even higher than current earnings estimates." http://247wallst.com/healthcare-business/2014/04/02/biotech-giants-now-priced-like-old-world-drug-stocks/#ixzz2xVYRfij8 Follow us: @247wallst on Twitter | 247wallst on Facebook
seems like i got in at the right time, 283p. currently at about 15% discount to NAV which i think will continue to rise in the coming weeks.
Sadly yes. Needless to say the general sentiment has affected IBT. I'm sure we shall see a turn around. It's a Growth Area without doubt.
Shame after the consistent gains over the past few months, but I'm a great believer in this sector for the future and of life sciences in general and that makes the optimism justified.
Absolutely. Huge pullback! Hopefully the worst of it is over now and should see a bit of stability. Time will tell though.
Am I right in thinking that biotechs have been hammered in the States
Is that right?
Wednesday 19 March___ Cum' Income 379.37 ___Ex' Income 382.02
See above or on ___ http://www.investegate.co.uk/intnl--biotechnology--ibt-/rns/portfolio-update/201403201205558051C/
Discount looks very tempting, may increase a bit more today, looks like a good buy.